|
SEC23B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.0929041246236E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.94279997539826E-09 |
| Normal-vs-Stage2 |
5.139800E-03 |
| Normal-vs-Stage3 |
1.36557432028894E-13 |
| Normal-vs-Stage4 |
2.67470001702463E-09 |
| Stage1-vs-Stage2 |
8.915700E-02 |
| Stage1-vs-Stage3 |
9.155400E-03 |
| Stage1-vs-Stage4 |
6.138000E-02 |
| Stage2-vs-Stage3 |
5.340100E-03 |
| Stage2-vs-Stage4 |
9.562400E-03 |
| Stage3-vs-Stage4 |
8.781000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.66133814775094E-15 |
| Normal-vs-AfricanAmerican |
6.877100E-03 |
| Normal-vs-Asian |
2.08180000016434E-07 |
| Caucasian-vs-AfricanAmerican |
1.299190E-01 |
| Caucasian-vs-Asian |
8.447400E-01 |
| AfricanAmerican-vs-Asian |
1.790780E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.56129603374234E-11 |
| Normal-vs-Female |
1.80079995359961E-09 |
| Male-vs-Female |
8.348300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.23790000472468E-08 |
| Normal-vs-Age(41-60Yrs) |
4.22030188573785E-11 |
| Normal-vs-Age(61-80Yrs) |
6.47279999599348E-08 |
| Normal-vs-Age(81-100Yrs) |
1.092220E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.304400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.048600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.747600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.736800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.251000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.383200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.317000E-03 |
| Classical-VS-Follicular |
5.815600E-03 |
| Classical-VS-Other |
9.510100E-02 |
| Classical-VS-Normal |
2.98683300314906E-12 |
| Tall-VS-Follicular |
1.66992999999227E-05 |
| Tall-VS-Other |
5.919400E-01 |
| Tall-VS-Normal |
3.84281495513505E-12 |
| Follicular-VS-Other |
4.739700E-02 |
| Follicular-VS-Normal |
3.959700E-03 |
| Other-VS-Normal |
7.97650000000649E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.75229999960425E-07 |
| Normal-vs-N1 |
6.15310025153804E-11 |
| N0-vs-N1 |
3.098100E-03 |
|
|
